Due to their early elevations in the blood of stroke patients and because time is one of the crucial parameters for tPA administration, the performances of GST-π, NDKA and DJ-1 were also investigated for discriminating patients treated with tPA (early ischemic and SUO patients, N = 12) vs. ineligible patients (late ischemic, TIA and stroke-mimicking condition patients, N = 102). The gene discussed is GSTP1; the disease is stroke disorder.